TNXP stock forecast, quote, news & analysis
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases... Show more
Tonix Pharmaceuticals (TNXP) Stock Analysis: TONMYA's Post-Launch Momentum
Key Takeaways
- Tonix Pharmaceuticals launched TONMYA, the first new FDA-approved fibromyalgia treatment in over 15 years, marking a shift to commercial-stage operations.
- Recent Phase 3 RESILIENT data presentation reinforced TONMYA's efficacy in reducing pain, improving sleep, and fatigue.
- A $20 million registered direct offering provided funding amid early commercialization efforts.
- Stock trades near $15, within a 52-week range of $6.76–$69.97, reflecting volatility post-approval and launch.
- Analysts maintain buy ratings with price targets around $70, citing pipeline potential.
- Pipeline includes Phase 2-ready assets like TNX-102 SL for depression and TNX-4800 for Lyme disease prevention.
Current Market Snapshot
Tonix Pharmaceuticals (TNXP) stock has navigated volatility in recent trading sessions, stabilizing around the mid-teens amid its transition to a revenue-generating biotech. The share price reflects early commercialization of TONMYA, its flagship non-opioid analgesic for fibromyalgia, alongside ongoing pipeline advancements. Trading volume remains moderate, indicative of investor focus on launch execution and clinical updates. Broader biotech sector dynamics, including non-opioid pain therapy demand, support sentiment, though dilution from recent capital raises tempers gains. The stock's position within its wide 52-week range underscores sensitivity to news flow and market cycles.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from hundreds available that analyze and trade thousands of tickers across diverse strategies. These bots employ varied approaches—ranging from short-term momentum and volatility plays to sector rotations and swing trades—adapting to current market conditions like biotech volatility or sector shifts. Highlighted performers often boast impressive stats, such as annualized returns up to 227%, win rates of 70–95%, and profit factors exceeding 3.0, particularly in high-momentum areas like semiconductors, biotech, and leveraged ETFs. Only the most suitable bots, demonstrating consistent outperformance against benchmarks like the S&P 500, earn a spot in this dynamic lineup. Explore Trending AI Robots to identify tools tailored for stocks like TNXP amid fluctuating conditions.
Recent Developments Driving TNXP Price Action
Tonix Pharmaceuticals (TNXP) has seen heightened activity in recent weeks, centered on its commercial launch of TONMYA and supporting clinical disclosures. On January 30, 2026, the company presented detailed Phase 3 RESILIENT trial data at the Non-Opioid Pain Therapeutics Summit, highlighting TONMYA's (cyclobenzaprine HCl sublingual tablets) statistically significant pain reduction (p<0.0001, effect size 0.38) over 14 weeks in 456 patients, alongside improvements in sleep quality, fatigue, and overall fibromyalgia impact. This reinforced the drug's profile following FDA approval on August 15, 2025—the first new fibromyalgia therapy in over 15 years—and its commercial availability since November 17, 2025, at a wholesale acquisition cost of up to $1,860 monthly.
The presentation sustained positive sentiment but coincided with price consolidation around $15–$18, as seen in historical data showing dips from $19 peaks in late January to $16 by early February. Earlier, on December 29, 2025, Tonix priced a $20 million registered direct offering of 615,025 shares at $16.26, led by Point72, bolstering cash for commercialization. This infusion addressed funding needs but introduced dilution pressures, contributing to subsequent pullbacks amid low single-digit percentage declines in recent sessions.
On January 6, 2026, Tonix announced presentations at two investor conferences, amplifying visibility for TONMYA's rollout and pipeline. Updates on TNX-4800, a Phase 2/3-ready monoclonal antibody for Lyme disease prevention, included plans for an FDA meeting in 2026, signaling progress in infectious diseases. Additionally, FDA IND clearance for TNX-102 SL in major depressive disorder positions it for Phase 2 trials targeting sleep-disrupted depression. These developments drove intermittent spikes, with shares climbing 4–5% post-news before profit-taking. Q3 2025 earnings met EPS expectations at -$3.59 on $3.29 million revenue, beating forecasts, yet persistent losses highlight burn rate risks. Institutional interest, like Point72's 9.2% stake, underpinned resilience, though biotech sector macroeconomic pressures and competition in non-opioids tempered upside. Overall, price action links directly to TONMYA momentum versus funding realities.
2026 Outlook and Key Factors to Monitor
As Tonix Pharmaceuticals advances through 2026, TONMYA's commercial traction will remain central, with investors tracking prescription growth, reimbursement dynamics, and peak sales potential in the underserved fibromyalgia market affecting millions. Early launch metrics, including uptake among the 10 million U.S. adults impacted, could validate its non-opioid differentiation amid rising demand for sleep-pain therapies. Pipeline milestones, such as Phase 2 initiation for TNX-102 SL in major depressive disorder and FDA interactions for TNX-4800 in Lyme prevention, offer catalysts in CNS and infectious diseases.
Analyst consensus leans buy, with targets near $70 citing expansion opportunities like acute stress disorder. Risks include cash burn, with Q4 2025 earnings due March 2026 projecting ongoing losses until revenue scales; dilution from further raises looms. Regulatory progress, manufacturing scale-up, and competitive positioning against entrenched pain treatments warrant scrutiny. Broader trends in non-opioid innovation and biotech M&A could enhance value, balanced against execution in a high-interest environment. Monitoring quarterly updates and trial readouts will shape trajectory.
TNXP in +2.38% Uptrend, rising for three consecutive days on June 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TNXP advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where TNXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNXP as a result. In of 64 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TNXP turned negative on May 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 32 similar instances when the indicator turned negative. In of the 32 cases the stock turned lower in the days that followed. This puts the odds of success at .
TNXP moved below its 50-day moving average on May 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TNXP crossed bearishly below the 50-day moving average on May 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNXP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TNXP broke above its upper Bollinger Band on May 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TNXP entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.816) is normal, around the industry mean (18.645). P/E Ratio (0.054) is within average values for comparable stocks, (35.882). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.679). TNXP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (6.920) is also within normal values, averaging (357.394).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing and manufacturing pharmaceuticals
Industry Biotechnology